Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, ...
